peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Hansa Medical to present IdeS at the World Orphan Drug Congress USA, April 24 in Washington D.C.

10 Apr 2014, 13:00
The presentation focusing on Hansa Medical’s lead drug-candidate IdeS’ capacity for desensitization prior to kidney transplantation is scheduled for 3:15 pm on April 24.

The World Orphan Drug Congress USA will be held on April 23-25 at the Grand Hyatt Washington, Washington D.C. For more information about the event please visit:

The company presentation’s emphasize will be on its lead drug-candidate IdeS, IdeS’ recent clinical Phase I results and IdeS’ forthcoming Phase II studies in 2014.


For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in clinical development, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.